Restricted accessResearch articleFirst published online 2005-6
The Use of Soluble,Salivary c- erb B-2 for the Detection and Post-operative Follow-up of Breast Cancer in Women: The Results of a Five-year Translational Research Study
Bigler LG, Streckfus CF (2004). A unique protein screening analysis of stimulated whole saliva from normal and breast cancer patients. Preclinica2(1):52–56.
2.
Bigler LG, Streckfus CF, Copeland L, Burns R, Dai X, Kuhn M, et al. (2002). The potential use of saliva to detect recurrence of disease in women with breast carcinoma. Oral Pathol Med31:421–431.
3.
Breuer B, Smith S, Thor A, Edgerton S, Osborne MP, Minick R, et al. (1998). ErbB-2 protein in sera and tumors of breast cancer patients. Breast Canc Res Treat49:261–270.
4.
Brinkley J, Copeland L, Streckfus C, Tucci M, Benguzzi H (2003). Sustained delivery of Her-2/neu antibody by TCPL delivery device using adult male rats as a model. Biomed Sci Inst39:324–328.
5.
Chen DX, Schwartz PE, Li XG, Yang Z (1988). Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol72:23–27.
6.
Chen DX, Schwartz PE, Li FQ (1990). Saliva and serum CA 125 assays for detecting malignant ovarian tumors. Obstet Gynecol75:701–704.
7.
Cornelissen G, Halberg F, Halberg E, Bingham C, Haus E, Bast RC Jr, et al. (1992). Toward a chronotherapy of ovarian cancer part III: salivary CA125 for chronotherapy by efficacy. Chronobiologia19:131–149.
8.
Hirata Y, Orth DN (1979). Epidermal growth factor (urogastrone) in human fluids: size heterogeneity. J Clin Endocrinol Metab48:673–679.
9.
Hutchens TW, Yip TT (1993). New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectrum7:576–580.
10.
Jenzano JW, Courts NF, Timko DA, Lundblad RL (1986a). Levels of glandular kallikrein in whole saliva obtained from patients with solid tumors remote from the oral cavity. J Dent Res65:67–70.
11.
Jenzano JW, Daniel PA, Kent RT, Leal JL, Koth D (1986b). Evaluation of kallikrein in human parotid and submandibular saliva. Arch Oral Biol31:627–628.
12.
Jenzano JW, Brown CK, Mauriello SM (1987). Temporal variations of glandular kallikrein, protein and amylase in mixed human saliva. Arch Oral Biol32:757–759.
13.
Jenzano JW, Coffey JC, Heizer WD, Lundblad RL, Scicli AG (1988). The assay of glandular kallikrein and prekallikrein human mixed saliva. Arch Oral Biol33:641–644.
14.
Kaufman E, Lamster IB (2002). The diagnostic applications of saliva—a review. Crit Rev Oral Biol Med13:197–212.
15.
Kelsey JL, Horn-Ross PL (1993). Breast cancer: magnitude of the problem and descriptive epidemiology. Epidemiol Rev15:7–16.
16.
Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL (1995). Efficacy of screening mammography: a meta-analysis. J Am Med Assoc273:149–154; comment in ACP J Club 123:34–35, 1995; J Am Med Assoc 274:381–382, 1995.
17.
Kosary CL, Ries LAG, Miller BA (1995). Cancer statistics review, 1973–1992. NIH Pub. No. (PHS)95-2789. Bethesda, MD: National Cancer Institute, National Institutes of Health.
18.
Kuerer HM, Thompson PA, Krishnamurthy S, Fritsche HA, Marcy SM, Babiera GV, et al. (2003). High and differential expression of HER2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer. Clin Canc Res9:601–605.
19.
Lawrence HP (2002). Salivary markers of systemic disease: noninvasive diagnosis of disease and monitoring of general health. J Can Dent Assoc8:170–174.
20.
Lenhard RE Jr (1996). Cancer statistics: a measure of progress. CA Cancer J Clin65:5–27; comment 46:5–27.
21.
Li J, Zhang Z, Rosenzweig J, Wang YY, Chan D (2002). Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem48:1296–1304.
22.
Madoz-Gurpide J, Wang H, Misek DE, Brichory F, Hanash SM (2001). Protein based microarrays: a tool for probing the proteome of cancer cells and tissues. Proteomics1:1279–1287.
23.
Mandel ID (1993). Salivary diagnosis: promises, promises. Ann NY Acad Sci694:1–10.
24.
McIntyre R, Bigler L, Dellinger T, Pfeifer M, Mannery T, Streckfus C (1999). Oral contraceptive usage and the expression of CA 15-3 and C-erbB-2 in the saliva of healthy women. Oral Surg Oral Med Oral Pathol Oral Radiol Endod88:687–690.
25.
Merchant M, Weinberger SR (2000). Recent advancements in surface enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis21:1164–1177.
26.
Michaelson JS, Halpern E, Kopans DB (1999). Breast cancer: computer simulation method for estimating optimal intervals for screening. Radiology212:551–560.
27.
Morrison AS (1993). Screening for cancer of the breast. Epidemiol Rev15:244–255.
28.
Nagler RM, Kerner H, Laufer D, Ben-Eliezer S, Minkov I, Ben-Itzhak O (2002). Squamous cell carcinoma of the tongue: the prevalence and prognostic roles of p53, Bcl-2, c-erbB-2 and apoptotic rate as related to clinical and pathological characteristics in a retrospective study. Cancer Lett186:137–150.
29.
Nagler RM, Kerner H, Ben-Eliezer S, Minkov I, Ben-Itzhak O (2003). Prognostic role of apoptotic, Bcl-2, c-erbB-2, and p53 tumor markers in salivary gland. Oncology64:389–398.
30.
National Institute of Dental and Craniofacial Research (1999). Workshop on development of new technologies for saliva and other oral fluid-based diagnostics. Airlie House Conference Center, Virginia, September 12–14, 1999, National Institutes of Health.
31.
National Institutes of Health (1997). Consensus development conference statement: breast cancer screening for women ages 40–49, January 21–23, 1997. J Natl Canc Inst89:1015–1020.
32.
Navarro MA, Mesia R, Diez-Gibert O, Rueda A, Ojeda B, Alonso MC (1997). Epidermal growth factor in plasma and saliva of patients with active breast cancer and breast cancer patients in follow-up compared with healthy women. Breast Cancer Res Treat42:83–86.
33.
Streckfus CF, Bigler LR (2002). Saliva as a diagnostic fluid. Oral Dis8:69–76.
34.
Streckfus C, Bigler L, Dellinger T, Pfeifer M, Rose A, Thigpen J (1999). CA 15-3 and c-erbB-2 presence in the saliva of women. Clin Oral Investig3:138–143.
35.
Streckfus C, Bigler L, Tucci M, Thigpen JT (2000a). A preliminary study of CA15-3, c-erbB-2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women with breast carcinoma. Cancer Invest18:101–109.
36.
Streckfus C, Bigler L, Dellinger T, Dai X, Kingman A, Thigpen JT (2000b). The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study. Clin Cancer Res6:2363–2370.
37.
Streckfus C, Bigler L, Dellinger T, Dai X, Cox WJ, McArthur A, et al. (2001). Reliability assessment of soluble c-erbB-2 concentrations in the saliva of healthy women and men. Oral Surg Oral Med Oral Pathol Oral Radiol Endod91:174–179.
38.
Streckfus CF, Bigler L, Dellinger T, Kuhn M, Chouinard N, Dai X (2004). The expression of the c-erbB-2 receptor protein in glandular salivary secretions. J Oral Pathol Med33:595–600.
39.
Tabak LA (2001). A revolution in biomedical assessment: the development of salivary diagnostics. J Dent Educ65:1335–1339.
40.
Thesleff I, Viinikka L, Saxén L, Lehtonen E, Perheentupa J (1988). The parotid gland is the main source of human salivary epidermal growth factor. Life Sci43:13–18.
41.
US Department of Health and Human Services (2000a). Oral health in America: a report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, National Institute of Dental and Craniofacial Research, National Institutes of Health, pp. 279–280.
42.
US Department of Health and Human Services (2000b). Healthy people 2010. 2nd ed. With understanding and improving health and objectives for improving health. 2 vols. Washington, DC: US Government Printing Office, November.
43.
Visco C, Bei R, Moriconi E, Gianni W, Kraus MH, Muraro R (2000). ErbB2 immune response in breast cancer patients with soluble receptor ectodomain. Am J Pathol156:1417–1424.
44.
Wick MR, Ockner DM, Mills SE, Ritter JH, Swanson PE (1998). Homologous carcinomas of the breasts, skin, and salivary glands. A histologic and immunohistochemical comparison of ductal mammary carcinoma, ductal sweat gland carcinoma and salivary duct carcinoma. Am J Clin Pathol109:75–84.
45.
Zabrecky JR, Lam T, Mckenzie SJ, Carney W (1991). The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem266:1716–1720.
46.
Zapka JG, Stoddard AM, Costanza ME, Greene HL (1989). Breast cancer screening by mammography: utilization and associated factors. Am J Publ Health79:1499–1502.